

1 NOTE: main changes compared to the previous version:

- 2 • BACT Working Party (Bacteriophages) added: new working party
- 3 • ROP Working Party (Rules of Procedure) added: re-activation
- 4 • GEL working party (Gelatin): put dormant

5

6

## TERMS OF REFERENCE AND PROFILE FOR MEMBERS OF GROUPS OF EXPERTS AND WORKING PARTIES

7

8

9 *The terms of reference and profiles shown below have been drafted by the Presidium to aid national authorities*  
10 *when making proposals for appointment. In addition to the profile described, national authorities should also*  
11 *ensure that the experts proposed are available to attend meetings and are prepared to draft and/or verify*  
12 *monographs and general chapters and when required in the profile, have access to a laboratory for*  
13 *experimental verifications.*

14 *Each group of experts and working party will advise the Commission and other groups of experts and working*  
15 *parties where relevant, according to their expertise and contribute to the maintenance of the relevant technical*  
16 *guide where appropriate.*

17 *The chairs of the following groups are members of the PCM working party: Groups 6, 7, 9, 10A/B/C/D, 11, 13H,*  
18 *14, 17, P4 and MG WP. The Chair of the Ph. Eur. Commission is chairing the PCM and ROP working parties.*  
19 *The chairs of the other groups of experts and working parties may be invited on an ad hoc basis, depending on*  
20 *the agenda.*

21 *In the context of this document, the term “regulatory authority” encompasses OMCLs, licensing authorities,*  
22 *NPAs and/or inspectorates.*

23

24	Group of Experts No. 1 (Microbiology).....	4
25	Group of Experts No. 6 (Biological and Biotechnological products) .....	4
26	Group of Experts No. 6B (Human Plasma and Plasma Products).....	5
27	Group of Experts No. 7 (Antibiotics).....	5
28	Group of experts No. 9 (Inorganic Chemistry) .....	6
29	Group of Experts No. 9G (Medicinal Gases).....	6
30	Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic products).....	6
31	Group of Experts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic products) .....	7
32	Group of Experts No. 12 (Dosage forms and pharmaceutical technical procedures).....	7
33	Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Preparations).....	8
34	Group of Experts No. 13H (Fatty oils and derivatives, polymers).....	8
35	Group of Experts No. 14 (Radiopharmaceutical Preparations).....	9
36	Group of Experts No. 15 (Human Vaccines and Sera) .....	9
37	Group of Experts No. 15V (Veterinary Vaccines and Sera) .....	10
38	Group of Experts No. 16 (Plastic materials, plastic containers and closures).....	10
39	Group of Experts 17 (Medicinal products containing chemically defined active substances).....	10
40	Group of Experts P4.....	11
41	ALG Working Party (Allergens).....	11
42	BACT Working Party (Bacteriophages) .....	11
43	BET Working Party (Bacterial Endotoxin Test).....	12
44	BSR Working Party (Bovine serum).....	12
45	CE Working Party (Capillary Electrophoresis).....	13
46	CEL Working Party (Cellulose).....	13
47	COL Working Party (Colour determination) .....	14
48	CRB Working Party (Carbohydrates) .....	14
49	CST Working Party (Chromatographic separation techniques).....	14

1	CTP Working Party (Cell Therapy Products) .....	15
2	DIA Working party (Dialysis) .....	15
3	EXP Working Party (Excipient performance).....	16
4	EXT Working Party (Extracts).....	16
5	GLS Working Party (Glass Containers).....	16
6	GTP Working Party (Gene Therapy Products) .....	17
7	HM Working Party (Heavy metals) .....	17
8	HMM Working Party (Homoeopathic Manufacturing Methods).....	18
9	HOM Working Party (Homoeopathic Raw Materials and Stocks) .....	18
10	ICP Working Party (Inductively-Coupled Plasma ).....	18
11	INH Working Party (Inhalations).....	18
12	LEC Working Party (Lecithins) .....	19
13	MAB Working Party (Monoclonal Antibodies).....	19
14	MG Working Party (General methods).....	20
15	MYC Working Party (Mycoplasma).....	20
16	NBC Working Party (Non-Biological Complex Drugs) .....	20
17	P4BIO Working Party (P4 Bio) .....	21
18	PA Working Party (Pyrrolizidine alkaloids) .....	21
19	PaedF Working Party (European Paediatric Formulary).....	21
20	PAT Working Party (Process Analytical Technology) .....	22
21	POW Working Party (Powder Characterisation) .....	22
22	PRP Working Party (Precursors for Radiopharmaceutical Preparations) .....	23
23	PST Working Party (Pesticide Residues).....	23
24	ROP Working Party (Rules of Procedure) .....	23
25	SDA Working Party (Spectroscopy and Data Analysis).....	24
26	SIT Working Party (Second identification test) .....	24
27	ST Working Party (Standard Terms) .....	25
28	SUT Working Party (Sutures).....	25
29	TCM Working Party (Traditional Chinese Medicines).....	25
30	VIT Working Party (Vitamins) .....	26
31	WAT Working Party (Water).....	26
32	TERMS OF REFERENCE AND PROFILE FOR MEMBERS OF “DORMANT” WORKING PARTIES:.....	27
33	CND Working Party (Conductivity) .....	27
34	CRP Working party (Production and compounding of radiopharmaceutical preparations).....	27
35	GEL Working Party (Gelatin).....	27
36	HCP Working Party (Host-Cell Proteins) .....	28
37	HFA Working Party (Propellant Gases).....	28
38	LBP Working Party (Live Biotherapeutic Products) .....	28
39	MQH Working Party (Microbiological Quality of Herbal Drugs).....	29
40	MSL Working Party (Mesilates).....	29
41	NMR Working Party (Nuclear Magnetic Resonance Spectrometry) .....	29
42	PHP Working Party (Pharmaceutical Preparations (general monograph)) .....	30
43	RCG Working Party (Raw Materials for the production of Cellular and gene transfer products) .....	30
44	SRP Working Party (Special Revision Programme) .....	30
45	STA Working Party (Statistics) .....	31
46	WXT Working Party (Water for Extracts).....	31

1

2 **Group of Experts No. 1 (Microbiology)**3 *Terms of reference*

- 4 • Drafting and revision of general chapters in the field of microbiology
- 5 • Advising the Commission on questions related to microbiological quality, including quality attributes in  
6 monographs drafted by other groups of experts and working parties
- 7 • International harmonisation of general chapters in the field of microbiology
- 8 • Drafting and revision of general chapters in the field of alternative microbiological methods (the so  
9 called “rapid” methods)
- 10 • Assessment of proposed examples in view of their inclusion in document: “Examples of validation  
11 protocols for alternative microbiological methods according to chapter 5.1.6”, to be published on the  
12 EDQM website.

13 *Profile for experts*

- 14 • Current expertise in microbiological analytical methods, related to quality control of active substances,  
15 excipients and medicinal products and in development of control methods
- 16 • Several years of experience in one or more of the following fields
  - 17 ○ Microbiological quality control in a pharmaceutical manufacturing setting, in a hospital  
18 environment or in an independent testing laboratory
  - 19 ○ Market surveillance of microbiological quality in a regulatory authority
  - 20 ○ Assessment of the relevant parts of applications for marketing authorisation
  - 21 ○ Development of microbiological control methods in a research and development environment

22 *Profile for ad-hoc specialists on alternative microbiological methods (please indicate this field of expertise on  
23 the nomination form, if applicable)*

- 24 • Current expertise in microbiological analytical methods, related to quality control of active substances,  
25 excipients and medicinal products and in development of control methods
- 26 • Several years of experience in one or more of the following fields:
  - 27 ○ Validation of alternative microbiological methods in a pharmaceutical manufacturing setting,  
28 in a hospital environment or in an independent testing laboratory
  - 29 ○ Market surveillance of microbiological quality in a regulatory authority using alternative  
30 microbiological methods
  - 31 ○ Assessment of the relevant parts of applications for marketing authorisation
  - 32 ○ Development of alternative microbiological control methods in a research and development  
33 environment

34 **Group of Experts No. 6 (Biological and Biotechnological products)**35 *Terms of reference*

- 36 • Drafting and revision of texts in the field of biological products, biotechnological products, synthetic  
37 peptides including glycan mapping
- 38 • International harmonisation of general chapters in the field of biological products

39 *Profile for experts*

- 40 • Current expertise in quality control of biological products, biotechnological products, peptides
- 41 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
42 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of  
43 texts
- 44 • Several years of experience in one or more of the following fields:
  - 45 ○ Quality control of biological products, biotechnological products, peptides in a pharmaceutical  
46 manufacturing setting

- 1           ○ Quality control in a regulatory authority
- 2           ○ Quality control of biological or biotechnological products in an independent testing laboratory
- 3           ○ Development of methods for control of biological products, biotechnological products, peptides in a research and development environment
- 4
- 5           ○ Method development and verification in a regulatory authority
- 6           ○ Assessment of the relevant parts of application for marketing authorisation of biological and
- 7           biotechnological products within a medicines agency

8 *Profile for glycan mapping ad-hoc specialists (please indicate this field of expertise on the nomination form, if*  
 9 *applicable)*

- 10           • Current expertise in pharmaceutical analytical methods, related to quality control of glycoproteins and
- 11           in development of control methods
- 12           • Several years of experience in one or more of the following fields:
  - 13           ○ Quality control of glycoproteins in a pharmaceutical manufacturing setting
  - 14           ○ Market surveillance of quality of glycoproteins in a regulatory authority
  - 15           ○ Pharmaceutical quality control of glycoproteins in an independent testing laboratory
  - 16           ○ Assessment of the relevant parts of application for marketing authorisation of biological and
  - 17           biotechnological products within a medicines agency
  - 18           ○ Method development and verification in a regulatory authority
  - 19           ○ Development of control methods for glycoproteins in a research and development environment

## 20 **Group of Experts No. 6B (Human Plasma and Plasma Products)**

21 *Terms of reference*

- 22           • Drafting and revision of texts in the field of blood products

23 *Profile for experts*

- 24           • Current expertise in the field of blood products, notably related to quality control of and development of
- 25           control methods
- 26           • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 27           monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of
- 28           texts
- 29           • Several years of experience in one or more of the following fields:
  - 30           ○ Quality control of blood products in a pharmaceutical or bulk manufacturing setting
  - 31           ○ Batch release or market surveillance of Human Blood, Plasma and Plasma Products in a
  - 32           regulatory authority
  - 33           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
  - 34           agency
  - 35           ○ Quality control of blood products in an independent testing laboratory
  - 36           ○ Method development and verification in a regulatory authority
  - 37           ○ Development of methods for control Human Plasma and Plasma Products in a research and
  - 38           development environment

## 39 **Group of Experts No. 7 (Antibiotics)**

40 *Terms of reference*

- 41           • Drafting and revision of texts in the field of antibiotic active substances
- 42           • Provision of expertise in the field of antibiotics to Group 17 where relevant

43 *Profile for experts*

- 44           • Current expertise in the fields of antibiotics
- 45           • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 46           monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of
- 47           texts

- 1 • Several years of experience in one or more of the following fields:
- 2 ○ Quality control of antibiotics in a pharmaceutical manufacturing setting
- 3 ○ Quality control of antibiotics in a bulk manufacturing setting
- 4 ○ Quality control of antibiotics in a regulatory authority
- 5 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
- 6 agency
- 7 ○ Quality control of antibiotics in an independent testing laboratory
- 8 ○ Development of methods for control of antibiotics in a research and development environment
- 9 ○ Method development and verification in a regulatory authority

#### 10 **Group of experts No. 9 (Inorganic Chemistry)**

##### 11 *Terms of reference*

- 12 • Drafting and revision of monographs in the field of inorganic substances
- 13 • International harmonisation of monographs

##### 14 *Profile for experts*

- 15 • Current expertise in pharmaceutical analytical methods, related to quality control of inorganic
- 16 substances and in development of control methods
- 17 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 18 monographs, for example ICP and/or AAS. **Essential:** Active involvement in laboratory verification of
- 19 test methods and drafting of texts.
- 20 • Several years of experience in one or more of the following fields:
- 21 ○ Quality control of inorganic substances in a pharmaceutical or bulk manufacturing setting
- 22 ○ Market surveillance of quality in a regulatory authority
- 23 ○ Pharmaceutical quality control in an independent testing laboratory
- 24 ○ Development of methods for control of inorganic substances in a research and development
- 25 environment
- 26 ○ Method development and verification in a regulatory authority

#### 27 **Group of Experts No. 9G (Medicinal Gases)**

##### 28 *Terms of reference*

- 29 • Drafting and revision of texts in the field of medicinal gases

##### 30 *Profile for experts*

- 31 • Current expertise in the field of medicinal gases
- 32 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 33 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of
- 34 texts
- 35 • Several years of experience in one or more of the following fields:
- 36 ○ Quality control of medicinal gases in a pharmaceutical manufacturing, hospital or industrial
- 37 setting
- 38 ○ Quality control in a regulatory authority
- 39 ○ Development of methods for control of medicinal gases in a research and development
- 40 environment

#### 41 **Group of Experts No. 10A/B/C/D (Organic chemistry – synthetic and semi-synthetic products)**

##### 42 *Terms of reference*

- 43 • Drafting and revision of monographs in the field of synthetic and semi-synthetic organic substances
- 44 • If needed, provide expertise in the field of organic chemistry to Group 17

1 *Profile for experts*

- 2 • Current expertise in pharmaceutical analytical methods, related to quality control of synthetic and semi-  
3 synthetic organic substances and in development of control methods
- 4 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
5 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of  
6 texts.
- 7 • Several years of experience in one or more of the following fields:
  - 8 ○ Quality control in a pharmaceutical manufacturing setting
  - 9 ○ Quality control of synthetic and semi-synthetic organic products in a bulk manufacturing  
10 setting
  - 11 ○ Market surveillance of quality in a regulatory authority
  - 12 ○ Pharmaceutical quality control of synthetic and semi-synthetic organic substances, in an  
13 independent testing laboratory
  - 14 ○ Development of methods for control of synthetic and semi-synthetic organic substances in a  
15 research and development environment
  - 16 ○ Group 10D: development of control methods for amino-acids
  - 17 ○ Method development and verification in a regulatory authority

18 **Group of Experts No. 11 (Organic chemistry – natural, semi-synthetic and synthetic products)**

19 *Terms of reference*

- 20 • Drafting and revision of monographs in the field of natural, semi-synthetic and synthetic organic  
21 substances
- 22 • Provision of expertise in the field of organic chemistry to the Group 17 where relevant

23 *Profile for experts*

- 24 • Current expertise in pharmaceutical analytical methods, related to quality control of natural, semi-  
25 synthetic and synthetic organic substances, and in development of control methods
- 26 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
27 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of  
28 texts.
- 29 • Several years of experience in one or more of the following fields:
  - 30 ○ Quality control in a pharmaceutical manufacturing setting
  - 31 ○ Quality control of natural, semi-synthetic and synthetic organic substances in a bulk  
32 manufacturing setting
  - 33 ○ Market surveillance of quality in a regulatory authority
  - 34 ○ Pharmaceutical quality control in an independent testing laboratory
  - 35 ○ Development of methods for control of natural, semi-synthetic and synthetic organic  
36 substances in a research and development environment
  - 37 ○ Method development and verification in a regulatory authority

38 **Group of Experts No. 12 (Dosage forms and pharmaceutical technical procedures)**

39 *Terms of reference*

- 40 • Drafting and revision of dosage form monographs and pharmaceutical technical procedures
- 41 • Maintenance of dosage form related International Harmonisation topics such as:
  - 42 ○ uniformity of dosage units
  - 43 ○ dissolution
  - 44 ○ disintegration
- 45 • Particulate contamination: visible and sub-visible particles
- 46 • Provision of expertise in the field of pharmaceutical technology to other groups where relevant

1 *Profile for experts*

- 2 • Current expertise in pharmaceutical development and control methods applied during manufacture and  
3 to finished pharmaceutical preparations, in the relevant specialities defined in the terms of reference
- 4 • Several years of experience in one or more of the following fields:
- 5 ○ Development and quality control of pharmaceutical preparations in an industrial setting
- 6 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
7 agency
- 8 ○ Development of methods for testing of pharmaceutical preparations in a research and  
9 development environment
- 10 ○ Method development and verification in a regulatory authority

11 **Group of Experts No. 13A/B (Herbal Drugs and Herbal Drug Preparations)**

12 *Terms of reference*

- 13 • Drafting and revision of texts in the field of herbal drugs and herbal drug preparations

14 *Profile for experts*

- 15 • Current expertise in pharmaceutical analytical methods, related to quality control of herbal drugs and  
16 herbal drug preparations and in development of control methods
- 17 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
18 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of  
19 texts.
- 20 • Several years of experience in one or more of the following fields:
- 21 ○ Quality control of herbal drugs and herbal drug preparations in a pharmaceutical  
22 manufacturing or bulk manufacturing setting
- 23 ○ Market surveillance of quality of herbals in a regulatory authority
- 24 ○ Assessment of the relevant parts of applications for marketing authorisation of herbal  
25 medicinal products within a medicines agency
- 26 ○ Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent  
27 testing laboratory
- 28 ○ Development of methods for control of herbal drugs in a research and development  
29 environment
- 30 ○ Method development and verification in a regulatory authority

31 **Group of Experts No. 13H (Fatty oils and derivatives, polymers)**

32 *Terms of reference*

- 33 • Drafting and revision of texts in the field of:
- 34 ○ surfactants
- 35 ○ fatty oils, fats and waxes
- 36 ○ fatty acids, fatty alcohols and their esters/ethers
- 37 ○ macrogols, macrogol derivatives and other polymers (i.e. carbomers)
- 38 ○ Paraffins
- 39 • International Harmonisation of the relevant monographs

40 *Profile for experts*

- 41 • Current expertise in pharmaceutical analytical methods, related to quality control in the relevant  
42 specialities defined in the terms of reference
- 43 • Member of a regulatory authority, universities or the pharmaceutical/chemical industries
- 44 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
45 monographs,  
46 **Essential:** Active involvement in laboratory verification of test methods and drafting of texts
- 47 • Several years of experience in one or more of the following fields:

- 1           ○ Quality control in a pharmaceutical manufacturing setting
- 2           ○ Quality control of fats etc. in a bulk manufacturing setting
- 3           ○ Market surveillance of quality in a regulatory authority
- 4           ○ Pharmaceutical quality control of fats etc. in an independent testing laboratory
- 5           ○ Development of methods for control of fats etc. in a research and development environment
- 6           ○ Method development and verification in a regulatory authority

#### 7 **Group of Experts No. 14 (Radiopharmaceutical Preparations)**

##### 8 *Terms of reference*

- 9           • Drafting and revision of texts in the field of radiopharmaceutical preparations

##### 10 *Profile for experts*

- 11          • Current expertise in pharmaceutical analytical methods, related to quality control of radiopharmaceutical preparations and in development of control methods
- 12
- 13          • Access to laboratory facilities for verification and validation of methods proposed for inclusion in monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of texts
- 14
- 15
- 16          • Several years of experience in one or more of the following fields:
  - 17           ○ Quality control of radiopharmaceutical preparations in a pharmaceutical manufacturing setting or in a hospital
  - 18
  - 19           ○ Market surveillance of quality of radiopharmaceutical preparations in a regulatory authority
  - 20           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - 21
  - 22           ○ Pharmaceutical quality control of radiopharmaceutical preparations in an independent testing laboratory
  - 23
  - 24           ○ Method development and verification in a regulatory authority

#### 25 **Group of Experts No. 15 (Human Vaccines and Sera)**

##### 26 *Terms of reference*

- 27          • Drafting and revision of texts in the field of vaccines and sera for human use
- 28          • Drafting and revision of monographs in the field of botulinum toxins

##### 29 *Profile for experts*

- 30          • Current expertise in analytical methods, related to quality control of vaccines and sera for human use and in development of control methods
- 31
- 32          • Several years of experience in one or more of the following fields:
  - 33           ○ Quality control of vaccines and sera for human use in a pharmaceutical manufacturing setting
  - 34           ○ Batch release and market surveillance of quality of vaccines and sera for human use in a regulatory authority
  - 35
  - 36           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - 37
  - 38           ○ Quality control of vaccines and sera for human use in an independent testing laboratory

##### 39 *Profile for botulinum toxins ad hoc specialists (please indicate this field of expertise on the nomination form, if applicable)*

- 41          • Current expertise in analytical methods for botulinum toxins and in development of control methods
- 42          • Several years of experience in one or more of the following fields:
  - 43           ○ Quality control of botulinum toxins in a pharmaceutical manufacturing setting
  - 44           ○ Batch release or market surveillance of quality of botulinum toxins in a regulatory authority
  - 45           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines agency
  - 46

- 1           ○ Pharmaceutical quality control of botulinum toxins in an independent testing laboratory
- 2           ○ Development of control methods for botulinum toxins in a research and development
- 3           environment

#### 4 **Group of Experts No. 15V (Veterinary Vaccines and Sera)**

##### 5 *Terms of reference*

- 6           • Drafting and revision of texts in the field of immunological veterinary medicinal products (IVMP)

##### 7 *Profile for experts*

- 8           • Current expertise in suitable standards for IVMP, in methods related to quality control of these products
- 9           and in development of control methods
- 10          • Several years of experience in one or more of the following fields:
  - 11           ○ Quality control of IVMP in a regulatory authority
  - 12           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
  - 13           agency
  - 14           ○ Batch release and market surveillance of quality in a regulatory authority
  - 15           ○ Development of methods for control of IVMP in a research and development environment
- 16          • Industry representatives are normally not appointed to Group of Experts No. 15V. They may be invited
- 17          to contribute to elaboration of texts during hearings organised on a case-by-case basis by the
- 18          Secretariat.

19

#### 20 **Group of Experts No. 16 (Plastic materials, plastic containers and closures)**

##### 21 *Terms of reference*

- 22          • Drafting and revision of texts in the field of plastic materials, plastic containers and closures

##### 23 *Profile for experts*

- 24          • Current expertise in the fields covered by the terms of reference
- 25          • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 26          texts, **Essential:** Active involvement in laboratory verification of test methods and drafting of texts
- 27          • Several years of experience in one or more of the following fields:
  - 28           ○ Quality control of plastic materials, plastic containers and closures in a pharmaceutical
  - 29           manufacturing setting
  - 30           ○ Quality control of plastic materials, plastic containers and closures in a regulatory authority
  - 31           ○ Quality control of plastic materials, plastic containers and closures in an independent testing
  - 32           laboratory
  - 33           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
  - 34           agency
  - 35           ○ Method development and verification in a regulatory authority

#### 36 **Group of Experts 17 (Medicinal products containing chemically defined active substances)**

##### 37 *Terms of reference*

- 38          • Drafting and revision of monographs on medicinal products containing chemically defined active
- 39          substances
- 40          • Drafting of monographs on active substances contained in these medicinal products if the monographs
- 41          are being elaborated in parallel and if deemed appropriate;
- 42          • Drafting and maintenance of the technical guide for the elaboration of monographs on medicinal
- 43          products containing chemically defined active substances
- 44          • Provision of expertise to other groups (such as Group P4) where relevant

##### 45 *Profile for experts*

- 46          • Current expertise in pharmaceutical analytical methods, related to quality control of medicinal products
- 47          containing chemically defined active substances and in development of such methods

- 1 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 2 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of
- 3 texts.
- 4 • Several years of experience in one or more of the following fields:
- 5     o Development and verification of test methods
- 6     o Quality control or development of medicinal products containing chemically defined active
- 7 substances
- 8     o Market surveillance testing
- 9     o Assessment of the relevant parts of applications for marketing authorisation within a medicines
- 10 agency

#### 11 **Group of Experts P4**

##### 12 *Terms of reference*

- 13 • Drafting and revision of monographs in the field of single-source active substances, excipients and
- 14 medicinal products with chemically defined active substances

##### 15 *Profile for experts*

- 16 • Current expertise in pharmaceutical analytical methods, related to quality control of active substances,
- 17 excipients and medicinal products (with chemically defined active substances), and in development of
- 18 control methods
- 19 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 20 monographs or access to licensing files, **Essential:** Active involvement in laboratory verification of test
- 21 methods and drafting of texts.
- 22 • Several years of experience in one or more of the following fields:
- 23     o Assessment of the relevant parts of applications for marketing authorisation
- 24     o Market surveillance studies in a regulatory authority
- 25     o Method development and verification in a regulatory authority
- 26 • Group P4 is restricted to regulators from Ph. Eur. Member states however industry representatives may
- 27 be invited to contribute by submission of data and interaction with the group via the Secretariat

#### 28 **ALG Working Party (Allergens)**

##### 29 *Objective*

- 30 • Drafting and revision of texts in the field of allergen products

##### 31 *Profile for experts*

- 32 • Current expertise in pharmaceutical analytical methods, related to quality control of allergens and in
- 33 development of control methods
- 34 • Several years of experience in one or more of the following fields:
- 35     o Quality control of allergen products in a pharmaceutical manufacturing setting
- 36     o Market surveillance of quality of allergen products in a regulatory authority
- 37     o Assessment of the relevant parts of applications for marketing authorisation within a medicines
- 38 agency
- 39     o Pharmaceutical quality control of allergen products in an independent testing laboratory
- 40     o Development of methods for control of allergens in a research and development environment

#### 41 **BACT Working Party (Bacteriophages)**

##### 42 *Terms of reference*

- 43 • To assess the feasibility, applicability and consequences of a general chapter on
- 44 Bacteriophages active pharmaceutical ingredient to allow the Ph. Eur. Commission to take a
- 45 decision on the next steps.

1

2 *Profile for experts*

- 3 • Current expertise in analytical methods related to quality control of bacteriophages and in
- 4 development of control methods
- 5 • Several years of experience in one or more of the following fields:
- 6 ○ Quality control of bacteriophages in a manufacturing setting
- 7 ○ Preparation and administration of bacteriophages manufactured in a non-industrial
- 8 way but of a quality compatible with clinical use (compassionate access)
- 9 ○ Development of bacteriophages for clinical use
- 10 ○ Method development and verification in a regulatory authority

11 **BET Working Party (Bacterial Endotoxin Test)**12 *Terms of reference*

- 13 • Drafting and revision of general chapters in the field of bacterial endotoxins
- 14 • Advising the Commission and expert groups on appropriate methods for the detection of bacterial
- 15 endotoxins or pyrogens in substances for pharmaceutical use or pharmaceutical preparations.
- 16 • Drafting and revision of general chapters in the field of the monocyte activation tests (MAT)
- 17 • International Harmonisation of the relevant texts

18 *Profile for experts*

- 19 • Several years of experience in one or more of the following fields:
- 20 ○ Quality control of parenteral preparations, active substances and/or excipients in a
- 21 pharmaceutical manufacturing setting
- 22 ○ Market surveillance of quality in a regulatory authority
- 23 ○ Pharmaceutical quality control in an independent testing laboratory
- 24 ○ Development of control methods for bacterial endotoxin test in a research and development
- 25 environment
- 26 ○ Access to laboratory facilities for verification and validation of methods proposed

27

28 *Profile for MAT ad hoc specialists (please indicate this field of expertise on the nomination form, if applicable)*

- 29 • Current expertise in practical application of the monocyte activation test
- 30 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 31 monographs,
- 32 • Several years of experience in one or more of the following fields:
- 33 ○ Quality control of parenteral preparations, active substances and/or excipients in a
- 34 pharmaceutical manufacturing setting
- 35 ○ Market surveillance of quality in a regulatory authority
- 36 ○ Pharmaceutical quality control in an independent testing laboratory
- 37 ○ Development of control methods for monocyte activation test in a research and development
- 38 environment
- 39 ○ Method development and verification in a regulatory authority

40 **BSR Working Party (Bovine serum)**41 *Terms of reference*

- 42 • Maintenance of the monograph *Bovine serum* (2262)
- 43 • Drafting and revision of other texts pertaining to bovine sera as appropriate

44 *Profile for experts*

- 45 • Current expertise in analytical methods related to quality control of bovine sera and in development of
- 46 control methods

- 1 • Several years of experience in one or more of the following fields:
- 2     o Quality control of bovine serum in a pharmaceutical manufacturing setting
- 3     o Market surveillance of quality in a regulatory authority
- 4     o Assessment of the relevant parts of applications for marketing authorisation within a medicines
- 5     agency
- 6     o Pharmaceutical quality control in an independent testing laboratory
- 7     o Development of methods for control of bovine serum in a research and development
- 8     environment

#### 9 **CE Working Party (Capillary Electrophoresis)**

##### 10 *Terms of reference*

- 11 • Revision of the chapter 2.2.47 *Capillary electrophoresis*
- 12 • Advising the Commission on questions related to capillary electrophoresis in monographs drafted by
- 13 other groups of experts and working parties
- 14 • International Harmonisation of the relevant texts

15

##### 16 *Profile for experts*

- 17 • Current expertise in *Capillary electrophoresis* techniques
- 18 • Several years of experience in the following fields:
- 19     o Quality control of active substances, excipients and medicinal products, using capillary
- 20     electrophoresis techniques, in a pharmaceutical manufacturing setting, in a regulatory authority
- 21     or in any other testing laboratory
- 22     o Development of capillary electrophoresis methods for control of active substances, excipients
- 23     and medicinal products in a research and development environment or at university
- 24     o Access to laboratory facilities for verification and validation of methods proposed for inclusion
- 25     in monographs **Essential**: Active involvement in laboratory verification of test methods and
- 26     drafting of texts

#### 27 **CEL Working Party (Cellulose)**

##### 28 *Terms of reference*

- 29 • Drafting and revision of monographs on cellulose and cellulose derivatives
- 30 • International harmonisation of monographs on cellulose and cellulose derivatives

##### 31 *Profile for experts*

- 32 • Current expertise in analytical methods for cellulose and cellulose derivatives and in development of
- 33 control methods
- 34 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 35 monographs, **Essential**: Active involvement in laboratory verification of test methods and drafting of
- 36 texts.
- 37 • Several years of experience in one or more of the following fields:
- 38     o Quality control of cellulose and cellulose derivatives in a pharmaceutical or other industrial
- 39     manufacturing setting
- 40     o Market surveillance of quality of cellulose and cellulose derivatives in a regulatory authority
- 41     o Quality control of cellulose and cellulose derivatives in a regulatory authority
- 42     o Development of control methods for cellulose and cellulose derivatives in a research and
- 43     development environment
- 44     o Method development and verification in a regulatory authority

**1 COL Working Party (Colour determination)***2 Terms of reference*

- 3 • Drafting and revision of monographs and texts in the field of instrumental determination of colour
- 4 (PDG item Q-07)
- 5 • Establishing correlation between measurement using Ph. Eur. Chapter 2.2.2 and the tristimulus type
- 6 instruments

*7 Profile for experts*

8 Several years of experience in one or more of the following fields:

- 9 ○ Users: Expertise in the use of tristimulus-type of colour measuring instruments in the field of
- 10 pharmaceutical development, quality control of pharmaceuticals, food, cosmetics or drinking
- 11 water
- 12 ○ Instrument suppliers: Personnel involved in user-support for practical application of
- 13 tristimulus-type instruments in the field of pharmaceutical development , quality control of
- 14 pharmaceuticals, food, cosmetics or drinking water
- 15 ○ Experience in research or university teaching related to instrumental colour determination of
- 16 liquids

**17 CRB Working Party (Carbohydrates)***18 Terms of reference*

- 19 • Drafting and revision of monographs in the field of carbohydrates
- 20 • International harmonisation of monographs

*21 Profile for experts*

- 22 • Current expertise in pharmaceutical analytical methods, related to quality control of carbohydrates and
- 23 in development of control methods
- 24 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 25 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of
- 26 texts.
- 27 • Several years of experience in one or more of the following fields:
- 28 ○ Quality control in a pharmaceutical or bulk manufacturing setting
- 29 ○ Market surveillance of quality in a regulatory authority
- 30 ○ Pharmaceutical quality control in an independent testing laboratory
- 31 ○ Development of control methods for carbohydrates in a research and development
- 32 environment
- 33 ○ Method development and verification in a regulatory authority

**34 CST Working Party (Chromatographic separation techniques)***35 Terms of reference*

- 36 • Revision of the chapter 2.2.46 *Chromatographic separation techniques*
- 37 • Revision of other chapters on chromatographic separation (e.g. 2.2.29, 2.2.30)
- 38 • International harmonisation of chapter 2.2.46 (PDG item G-20)
- 39 • Advising the Commission on questions related to chromatographic separation techniques in
- 40 monographs drafted by other groups of experts and working parties
- 41 • Co-operation with other groups of experts and working parties which use chromatographic separation
- 42 techniques where relevant

*43 Profile for experts*

- 44 • Current expertise in chromatographic separation techniques
- 45 • Several years of experience in one or more of the following fields:
- 46 ○ Chromatographic quality control of active substances and/or excipients in a pharmaceutical
- 47 manufacturing setting

- 1           ○ Development of chromatographic methods for control of active substances, excipients and
- 2           medicinal products in a research and development environment
- 3           ○ Market surveillance of quality in a regulatory authority
- 4           ○ Pharmaceutical quality control in an independent testing laboratory

## 5 **CTP Working Party (Cell Therapy Products)**

### 6 *Terms of reference*

- 7           • Revision of general chapter 2.7.29 *Nucleated cell count and viability* in order to update it with new
- 8           automated technologies for cell enumeration (e.g. image cytometry)
- 9           • Revision of Ph. Eur. texts (monographs or chapters) where it might be necessary to account for chapter
- 10          5.2.12 *Raw materials of biological origin for the production of cell-based and gene therapy medicinal*
- 11          *products*
- 12          • Evaluation of the need to revise the introductory statement of the monograph on parenteral preparations
- 13          (0520) by adding cell-based preparations to the list of preparations to which the monograph does not
- 14          necessarily apply, and if so, evaluation of the need for a general Ph. Eur. text dealing with cell-based
- 15          preparations
- 16          • Drafting and revision of other texts in the field of cell therapy products

### 17 *Profile for experts*

- 18          • Current expertise in analytical methods related to the development and quality control of cell therapy
- 19          products and/or tissue-engineered products and/or to the quality control of tissues for human use
- 20          • Several years of experience in one or more of the following fields:
- 21               ○ Development of cell therapy products and/or tissue-engineered products
- 22               ○ Quality control of cell therapy products and/or tissue-engineered products in a pharmaceutical
- 23               manufacturing setting or in a hospital environment and/or microbiological control of tissues
- 24               and organs used for human transplantation
- 25               ○ Assessment of applications for marketing authorisation of cell therapy and/or tissue-
- 26               engineered products
- 27               ○ Market surveillance of the quality of cell therapy products, tissue-engineered products and/or
- 28               tissues and organs used for human transplantation in a regulatory authority
- 29               ○ Pharmaceutical quality control in an independent testing laboratory
- 30               ○ Development of methods (e.g. microbiological methods) to control cell therapy products
- 31               and/or tissue-engineered products and/or tissues and organs used for human transplantation in
- 32               a research and development environment

33

## 34 **DIA Working party (Dialysis)**

### 35 *Terms of reference*

- 36          • Drafting and revision of texts in the field of preparations for dialysis

### 37 *Profile for experts*

- 38          • Current expertise in the field of preparations for dialysis
- 39          • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 40          monographs
- 41          • Several years of experience in one or more of the following fields:
- 42               ○ Quality control of preparations for dialysis in a pharmaceutical manufacturing setting or in a
- 43               hospital
- 44               ○ Quality control of preparations for dialysis in a regulatory authority
- 45               ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
- 46               agency
- 47               ○ Quality control of preparations for dialysis in an independent testing laboratory

- 1                   ○ Method development and verification in a regulatory authority

## 2 **EXP Working Party (Excipient performance)**

### 3 *Terms of reference*

- 4           • Drafting and maintaining the FRC (Functionality Related Characteristics) sections of monographs on  
5           excipients to reflect current best practices, in consultation with the appropriate Groups of Experts or  
6           Working Parties of the Ph. Eur.
- 7           • Review, where necessary, and maintenance of general chapter 5.15 FRCs of excipients to align it with  
8           current regulatory guidance (e.g. ICH Q8 guideline)
- 9           • Drafting and maintenance of the text on Co-processed excipients
- 10          • Review pharmacopoeial and other regulatory texts on general information on excipients with a view to  
11          proposing necessary additions and updates, where relevant

### 12 *Profile for experts*

- 13          • Current expertise in analytical methods (especially those included in the Ph. Eur. section 2.9.  
14          Pharmaceutical technical procedures), related to control of excipients and in development of control  
15          methods
- 16          • Several years of experience in one or more of the following fields:
- 17                  ○ Quality control of excipients in a bulk or pharmaceutical manufacturing setting
- 18                  ○ Pharmaceutical and excipient research and development
- 19                  ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines  
20                  agency
- 21                  ○ Development of control methods for excipients, comprising methods to determine excipient  
22                  performance (FRCs) in a research and development environment
- 23                  ○ Pharmaceutical quality control in an independent testing laboratory

## 24 **EXT Working Party (Extracts)**

### 25 *Terms of reference*

- 26          • Revision of the general monograph on *Extracts (0765)* with the aim of clarifying/improving the  
27          definitions and requirements of the different types of extracts whilst maintaining the established  
28          classification system of extracts

### 29 *Profile for experts*

- 30          • Several years of experience in one or more of the following fields:
- 31                  ○ Assessment of the relevant parts of applications for marketing authorisation of herbal  
32                  medicinal products within a medicines agency
- 33                  ○ Production or quality control of extracts for further use in herbal medicinal products
- 34                  ○ Production or quality control of herbal medicinal products containing extracts

## 35 **GLS Working Party (Glass Containers)**

### 36 *Terms of reference*

- 37          • Drafting and revision of texts in the field of glass containers

### 38 *Profile for experts*

- 39          • Current expertise in the production of glass containers, analytical methods, related to quality control of  
40          glass containers and in development of control methods
- 41          • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
42          general chapters
- 43          • Several years of experience in one or more of the following fields:
- 44                  ○ Quality control in a pharmaceutical manufacturing setting for control of glass containers
- 45                  ○ Production and/or Quality control of glass containers in an industrial setting
- 46                  ○ Market surveillance of quality in a regulatory authority

- 1           ○ Pharmaceutical quality control in an independent testing laboratory
- 2           ○ Development of control methods for control of glass containers in a research and development
- 3           environment

#### 4 **GTP Working Party (Gene Therapy Products)**

##### 5 *Terms of reference*

- 6           • Revision of the general chapter 5.14 *Gene transfer medicinal products for human use* (raw materials
- 7           part) to account for the chapter 5.2.12 *Raw materials of biological origin for the production of cell-*
- 8           *based and gene therapy medicinal products*; Evaluation of the general chapter 5.14 in the view of
- 9           development in the field within last decade and its potential revision
- 10          • Participation in elaboration/revision of transversal texts elaborated by other Groups of Experts or
- 11          Working Parties, (e.g. general chapter 2.6.35 Quantification and characterisation of residual host cell
- 12          DNA)
- 13          • Drafting and revision of other texts in the field of gene therapy

##### 14 *Profile for experts*

- 15          • Current expertise in analytical methods related to development and quality control of gene therapy
- 16          products and in development of control methods
- 17          • Several years of experience in one or more of the following fields:
- 18           ○ Development of gene therapy products
- 19           ○ Quality control of gene therapy products in a pharmaceutical manufacturing setting or in a
- 20           hospital environment
- 21           ○ Assessment of applications for marketing authorisation of gene therapy products
- 22           ○ Marketing surveillance of quality in a regulatory authority
- 23           ○ Pharmaceutical quality control in an independent testing laboratory
- 24           ○ Development of methods for control of gene therapy products in a research and development
- 25           environment

#### 27 **HM Working Party (Heavy metals)**

##### 28 *Terms of reference*

- 29          • Drafting and revision of the general chapter 5.20 Elemental impurities. In this context, identification of
- 30          technical issues which need to be addressed by ICP working party such as sample preparation and
- 31          instrumental determination by *atomic emission spectrometry, inductively coupled plasma - atomic*
- 32          *emission spectrometry* and *inductively coupled plasma - mass spectrometry* and which would require an
- 33          update of the respective general methods
- 34          • International harmonisation of chapter 2.4.20 (PDG item G-07)

##### 35 *Profile for experts*

- 36          • Up-to-date substantial expertise in pharmaceutical analytical methods, related to quality control of
- 37          active substances and excipients allowing a holistic view on the occurrence of metals from either
- 38          synthesis or contamination
- 39          • Several years of experience in one or more of the following fields:
- 40           ○ Quality control in a pharmaceutical manufacturing setting
- 41           ○ Quality control of synthetic and semi-synthetic organic products in a bulk manufacturing
- 42           setting
- 43           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
- 44           agency
- 45           ○ Pharmaceutical quality control of active substances and /or excipients in an independent
- 46           testing laboratory specialised in testing for metals as residues from synthesis or contaminants

## 1 **HMM Working Party (Homoeopathic Manufacturing Methods)**

### 2 *Terms of reference*

- 3 • Drafting and revision of monographs in the field of homoeopathic manufacturing methods

### 4 *Profile for experts*

- 5 • Knowledge of currently used homoeopathic manufacturing methods
- 6 • Several years of experience in one or more of the following fields:
  - 7 ○ Assessment of application for marketing authorisation of homoeopathic products within a
  - 8 medicines agency or equivalent
- 9 • Industry representatives are normally not appointed to the HMM Working Party. They may be invited
- 10 to contribute to elaboration of monographs during hearings organised on a case-by-case basis by the
- 11 Secretariat

## 12 **HOM Working Party (Homoeopathic Raw Materials and Stocks)**

### 13 *Terms of reference*

- 14 • Drafting and revision of texts in the field of homoeopathic raw materials and stocks

### 15 *Profile for experts*

- 16 • Current expertise in pharmaceutical analytical methods, related to quality control of homoeopathic raw
- 17 materials and stocks and in development of control methods
- 18 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 19 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of
- 20 texts
- 21 • Several years of experience in one or more of the following fields:
  - 22 ○ Quality control of homoeopathic raw materials and stocks in a pharmaceutical manufacturing
  - 23 setting
  - 24 ○ Assessment of applications for marketing authorisation of homoeopathic products within an
  - 25 agency
  - 26 ○ Quality control of homoeopathic raw materials and stocks in an independent testing laboratory
  - 27 ○ Development of methods for control of homoeopathic raw materials and stocks in a research
  - 28 and development environment
  - 29 ○ Method development, and verification in a regulatory authority

## 30 **ICP Working Party (Inductively-Coupled Plasma )**

### 31 *Terms of reference*

- 32 • Drafting and revision of texts in the field of *atomic absorption spectrometry, atomic emission*
- 33 *spectrometry, inductively coupled plasma - atomic emission spectrometry* and *inductively coupled*
- 34 *plasma - mass spectrometry*

### 35 *Profile for experts*

- 36 • Current expertise in the development, and application of analytical procedures involving the above
- 37 mentioned techniques
- 38 • Several years of experience in one or more of the following fields:
  - 39 ○ Quality control of herbal drugs, herbal drug preparations, synthetic, semi-synthetic, natural
  - 40 origin, biological or biotechnological products in a pharmaceutical setting
  - 41 ○ Quality control in a regulatory authority or an independent testing laboratory

## 42 **INH Working Party (Inhalations)**

### 43 *Terms of reference*

- 44 • Drafting and revision of monographs and general chapters in the field of preparations for inhalation
- 45 • International harmonisation of related general chapters

1 *Profile for experts*

- 2 • Current expertise in pharmaceutical analytical methods, related to quality control of preparations for  
3 inhalation and in development of control methods
- 4 • Several years of experience in one or more of the following fields:
  - 5 ○ Quality control of preparations for inhalation in a pharmaceutical manufacturing setting
  - 6 ○ Market surveillance of quality in a regulatory authority
  - 7 ○ Assessment of applications for marketing authorisation of preparations for inhalation within an  
8 agency
  - 9 ○ Development of control methods for control of preparations for inhalation in a research and  
10 development environment
  - 11 ○ Pharmaceutical quality control in an independent testing laboratory
  - 12 ○ Method development and verification in a regulatory authority

13 **LEC Working Party (Lecithins)**

14 *Terms of reference*

- 15 • Drafting and revision of monographs in the field of lecithins

16 *Profile for experts*

- 17 • Current expertise in pharmaceutical analytical methods, related to quality control of lecithins and in  
18 development of control methods
- 19 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
20 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of  
21 texts/
- 22 • Several years of experience in one or more of the following fields:
  - 23 ○ Quality control of lecithins in a pharmaceutical or bulk manufacturing setting
  - 24 ○ Market surveillance of quality in a regulatory authority
  - 25 ○ Pharmaceutical quality control in an independent testing laboratory
  - 26 ○ Development of control methods for lecithins in a research and development environment
  - 27 ○ Method development and verification in a regulatory authority

28 **MAB Working Party (Monoclonal Antibodies)**

29 *Terms of reference:*

- 30 • To undertake a pilot phase to elaborate general methods for analysis of monoclonal antibodies and  
31 individual monographs using the multisource approach (according to document PA/PH/Exp. MAB/T  
32 (14) 1)
- 33 • Drafting and revision of texts in the field of monoclonal antibodies

34 *Profile for experts*

- 35 • Current expertise in pharmaceutical analytical methods, related to quality control of monoclonal  
36 antibodies and in development of control methods
- 37 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
38 monographs or access to licensing files. **Essential:** Active involvement in laboratory verification of test  
39 methods and drafting of texts
- 40 • Several years of experience in one or more of the following fields:
  - 41 ○ Quality control of monoclonal antibodies in a pharmaceutical manufacturing setting
  - 42 ○ Market surveillance of quality in a regulatory authority
  - 43 ○ Assessment of applications for marketing authorisation of monoclonal antibodies within an  
44 agency
  - 45 ○ Development of control methods for control of monoclonal antibodies in a research and  
46 development environment
  - 47 ○ Pharmaceutical quality control in an independent testing laboratory

## 1 **MG Working Party (General methods)**

### 2 *Terms of reference*

- 3 • Drafting and revision of general chapters, particularly in the field of chemical and physico-chemical
- 4 analysis.
- 5 • If needed, requests the nomination of ad hoc specialists to create sub-groups for specific general
- 6 chapters on the work programme, and management of the activities for the elaboration or revision of
- 7 these general chapters within the sub-groups.
- 8 • Co-operation with other groups of experts and working parties which are in charge of elaboration and
- 9 revision of general chapters where relevant.
- 10 • Maintenance of template for general methods

### 11 *Profile for experts*

- 12 • Members of a regulatory authority, universities or the pharmaceutical/chemical industries
- 13 • Current expertise and extensive knowledge in pharmacopoeial methods and/or instruments used in the
- 14 quality control of active substances, excipients and/or medicinal products and in development of control
- 15 methods
- 16 • Several years of experience in one or more of the following fields:
  - 17 ○ Method development and verification in e.g. analytical or pharmaceutical development, a
  - 18 regulatory authority, or testing laboratory
  - 19 ○ Quality control of active substances, excipients and/or medicinal products
  - 20 ○ Market surveillance of quality of medicinal products in a regulatory authority
  - 21 ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
  - 22 agency

## 23 **MYC Working Party (Mycoplasma)**

### 24 *Terms of reference*

- 25 • Revision of general chapter 2.6.7 *Mycoplasmas* in order to update it with the current practices in the
- 26 field of mycoplasma testing

### 27 *Profile for experts*

- 28 • Current expertise in mycoplasma testing of medicinal products and in development of control methods
- 29 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 30 monographs,
- 31 • Several years of experience in one or more of the following fields:
  - 32 ○ Mycoplasma testing in a pharmaceutical manufacturing setting
  - 33 ○ Mycoplasma testing in an official control laboratory for medicines
  - 34 ○ Mycoplasma testing in an independent testing laboratory
  - 35 ○ Development of test methods for mycoplasmas in a research and development environment

## 36 **NBC Working Party (Non-Biological Complex Drugs)**

### 37 *Terms of reference*

- 38 • Elaboration and revision of monographs on non-biological complex drugs (e.g. nanoparticle
- 39 dispersions, like for example iron sucrose concentrated solution)

### 40 *Profile for experts*

- 41 • Current expertise in the development and/or quality control of non-biological complex drugs and in
- 42 development of control methods
- 43 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 44 monographs,
- 45 **Essential:** Active involvement in laboratory verification of test methods and drafting of texts and
- 46 • Several years of experience in one or more of the following fields:

- 1           ○ Quality control in a pharmaceutical manufacturing setting or in an independent testing
- 2           laboratory (e.g. Market surveillance of quality in a regulatory authority)
- 3           ○ Pharmaceutical and/or analytical development related to respective formulations
- 4           ○ Assessment of the relevant parts of applications for marketing authorisation within a medicines
- 5           agency

#### 6 **P4BIO Working Party (P4 Bio)**

##### 7 *Terms of reference*

- 8           • Drafting and revision of monographs in the field of single-source biologicals

##### 9 *Profile for experts*

- 10          • Group P4Bio is restricted to regulators from Ph. Eur. Member states however industry representatives
- 11          may be invited to contribute by submission of data and interaction with the group via the Secretariat
- 12          • Current expertise in pharmaceutical analytical methods, related to quality control of biologicals and in
- 13          development of control methods
- 14          • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 15          monographs or access to licensing files (essentially originating from CAP), **Essential:** Active
- 16          involvement in laboratory verification of test methods and drafting of texts and
- 17          • Several years of experience in one or more of the following fields:
- 18              ○ Quality control in a regulatory authority
- 19              ○ Assessment of the relevant parts (biologicals) of applications for marketing authorisation
- 20              ○ Market surveillance of quality in a regulatory authority

#### 21 **PA Working Party (Pyrrolizidine alkaloids)**

##### 22 *Terms of reference*

- 23          • Drafting of a general chapter allocated to the group by the Commission in the field of pyrrolizidine
- 24          alkaloids.
- 25          • Maintenance of the list of PA alkaloids which may be covered by the general chapter on PA alkaloids.

##### 26 *Profile for experts*

- 27          • Current expertise in PA analysis, related to quality control of herbal drugs and in development of
- 28          control methods.
- 29          • Access to laboratory facilities for quality control. Essential: active involvement in laboratory
- 30          verification of methods and drafting of texts
- 31          • Several years of experience in one or more of the following fields:
- 32              ○ Quality control of herbals in a pharmaceutical or bulk manufacturing setting, in a regulatory
- 33              authority or in any other specialised testing laboratory;
- 34              ○ Development and/or lab verification of control methods for analysis of pyrrolizidine alkaloids
- 35              in a research and development environment or in a regulatory authority.

#### 36 **PaedF Working Party (European Paediatric Formulary)**

##### 37 *Terms of reference*

- 38          • Elaboration, and revision of monographs on paediatric preparations according to criteria and guidelines
- 39          approved by the CD-P-PH
- 40          • Establishment and maintenance of a Technical Guide for the elaboration and maintenance of monographs on
- 41          paediatric preparations

##### 42 *Profile for experts*

- 43          • Current expertise in development of paediatric preparations (including toxicologists)
- 44          • Current expertise in analytical methods related to quality control of ingredients (APIs and excipients)
- 45          and preparations and in the development of such methods; Access to laboratory facilities for
- 46          verification of methods proposed for inclusion in monographs

- 1 • Current expertise in clinical/pharmacological treatment of several paediatric age groups
- 2 • Several years of experience in one or more of the following fields:
  - 3 ○ Pharmaceutical development and/or manufacturing of paediatric preparations (in a community
  - 4 or hospital pharmacy, research unit, or in pharmaceutical industry)
  - 5 ○ Method development and verification of medicinal preparations in a pharmaceutical
  - 6 manufacturing setting (including research and development), in a regulatory authority, in a
  - 7 community or hospital pharmacy or in an independent testing laboratory
  - 8 ○ Market surveillance of quality in a regulatory authority
  - 9 ○ Assessment of the relevant parts of applications for marketing authorisation of paediatric
  - 10 medicinal products (including safety assessment)
  - 11 ○ Elaboration/assessment of monographs for national paediatric formularies
  - 12 ○ Clinical/pharmacological treatment of children belonging to several age groups

### 13 **PAT Working Party (Process Analytical Technology)**

#### 14 *Terms of reference*

- 15 • Review and revision of existing general monographs and chapters of existing pharmacopoeial texts in
- 16 view of needs arising from Process Analytical Technology (PAT), Continuous Manufacturing (CM),
- 17 Real Time release testing (RTRT) or Quality by Design (QbD) concepts
- 18 • Identify and discuss the implication of the above mentioned concepts on the texts of European
- 19 Pharmacopoeia and make proposals to the Commission where needed
- 20 • Support and advise other group of experts and working parties where elements of the above mentioned
- 21 concepts are concerned.

#### 22 *Profile for experts*

- 23 • Expertise in chemical or pharmaceutical development and control methods applied during manufacture
- 24 and to active substances or finished pharmaceutical preparations
- 25 • Several years of experience in one or more of the following fields
  - 26 ○ Development of pharmaceutical preparations using PAT, CM, RTRT or QbD concepts in an
  - 27 industrial setting
  - 28 ○ Assessment of the relevant parts of applications for marketing authorisation containing PAT,
  - 29 CM, RTRT or QbD concepts within a medicines agency
  - 30 ○ Development of control strategies including PAT, CM, RTRT or QbD concepts approaches for
  - 31 testing of active substances or pharmaceutical preparations
  - 32 ○ Development of pharmaceutical preparations using modelling and chemometrics associated
  - 33 with the analytical aspects for PAT

### 34 **POW Working Party (Powder Characterisation)**

#### 35 *Terms of reference*

- 36 • Drafting and revision of general chapters in the field of powder characterisation
- 37 • International harmonisation of general chapters

#### 38 *Profile for experts*

- 39 • Current expertise in methods for powder characterisation, related to quality control of active substances
- 40 and excipients and in development of control methods
- 41 • Several years of experience in one or more of the following fields:
  - 42 ○ Quality control of active substances and excipients in a pharmaceutical manufacturing setting
  - 43 ○ Assessment of the relevant parts of applications for marketing authorisation
  - 44 ○ Market surveillance of quality in a regulatory authority
  - 45 ○ Development of methods for characterisation of powders in a research and development
  - 46 environment
  - 47 ○ Pharmaceutical quality control in an independent testing laboratory

1 **PRP Working Party (Precursors for Radiopharmaceutical Preparations)**

2 *Terms of reference*

- 3 • Drafting and revision of texts in the field of non-radioactive precursors for radiopharmaceutical  
4 preparations

5 *Profile for experts*

- 6 • Expertise in chemical, pharmaceutical and radiopharmaceutical methods, related to quality control of  
7 radiopharmaceutical preparations and their precursors
- 8 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
9 monographs. **Essential:** Active involvement in laboratory verification of test methods and drafting of  
10 texts
- 11 • Several years of experience in one or more of the following fields:
- 12 ○ Quality control of radiopharmaceutical preparations and their precursors
- 13 ○ Quality control of synthetic organic and/or inorganic products in a chemical or pharmaceutical  
14 setting
- 15 ○ Quality control in an independent testing laboratory
- 16 ○ Development of analytical procedures for the control of radiopharmaceutical preparations and  
17 their precursors

18 **PST Working Party (Pesticide Residues)**

19 *Terms of reference*

- 20 • Drafting and revision of texts in the field of pesticide residues
- 21 • Advising the Commission on acceptance criteria for pesticide residues to be included in monographs
- 22 • Maintenance of the list of pesticides tabled in general chapter on pesticide residues

23 *Profile for experts*

- 24 • Current expertise in pesticide analysis, related to quality control of active substances and excipients and  
25 in development of control methods
- 26 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
27 monographs
- 28 • Several years of experience in one or more of the following fields:
- 29 ○ Quality control for pesticide residues in herbals in a pharmaceutical or bulk manufacturing  
30 setting
- 31 ○ Market surveillance of quality in a regulatory authority
- 32 ○ Pharmaceutical quality control in an independent testing laboratory
- 33 ○ Development of control methods for analysis of pesticide residues in a research and  
34 development environment

35 **ROP Working Party (Rules of Procedure)**

36 *Terms of reference*

37 Addressing the following topic:

- 38 • Handling of official Ph. Eur. documents, information and data
- 39 • Implication of the EU General Data Protection Regulation (GDPR) on the Ph. Eur. code of practice and  
40 provision of contact details (incl. handbook)
- 41 • Pilot Projects and pilot phase: clarification of definition, process, criteria
- 42 • Review of the re-nomination process of members of Groups of Experts and Working Parties
- 43 • Post COVID-19 – Digital Transformation: opportunities for adjustment of working methods (e.g.  
44 establishment of electronic workflows, organisation of visio-conferences and webinars)

45 As the impact on the Rules of Procedure, on the Guide for work of the European Pharmacopoeia and on the  
46 Code of practice is not known yet, the work is carried out in two steps:

- 47 • The first step includes for each of the points highlighted above,

- 1 a. To clarify the remit or scope,
  - 2 b. To agree on the expected / wished outcome
  - 3 c. To assess the impact on the documents mentioned above (i.e. which section of which
  - 4 document)
  - 5 d. To report back to the Commission for the latter to decide to move to step 2 or not
- 6 • If the Commission agrees to move to step 2, the ROP WP would revise the impacted documents i.e. the
  - 7 Rules of Procedure and/or the Guide for work of the European Pharmacopoeia and/or the Code of
  - 8 Practice according to the decision taken by the Commission after step 1.

9 *Profile for experts*

- 10 • Members of national pharmacopoeia authorities of a Ph. Eur. Member state or delegations to the
  - 11 Commission.
- 12 The ROP WP is chaired by the Chair of the Ph. Eur. Commission.

13 **SDA Working Party (Spectroscopy and Data Analysis)**

14 *Terms of reference*

- 15 • Drafting and revision of general chapters in the fields of:
  - 16 o Measurement techniques relying on spectroscopy, with the exception of specific spectroscopic
  - 17 techniques where the drafting and revision of general chapters is allocated to other, more
  - 18 specialised groups of experts and working parties.
  - 19 o Chemical imaging techniques, e.g. spectral and multispectral imaging, electron microscopy,
  - 20 field effect and atomic force microscopies, optical and X-ray tomography, etc.
  - 21 o Chemometrics and data sciences techniques relying on multivariate data analysis, numerical
  - 22 methods, algorithmics, data modelling, data mining, artificial intelligence, etc., and image
  - 23 analysis techniques.
- 24 • to support and advise other group of experts and working parties where elements of the above
- 25 mentioned measurement and data analysis techniques are concerned and where relevant.

26 *Profile for experts*

- 27 • Current expertise in spectroscopy related to quality control of active substances, excipients or products,
- 28 in development of analytical control methods.
- 29 • Ideally, access to laboratory facilities for verification and validation of methods proposed for inclusion
- 30 in general chapters and monographs. **Essential:** Active involvement in laboratory verification of test
- 31 methods and drafting of texts Several years of experience in one or more of the following fields:
  - 32 o Use of spectroscopic techniques for pharmaceutical quality control in a pharmaceutical
  - 33 manufacturing setting, a regulatory authority or an independent testing laboratory.
  - 34 o Development of pharmaceutical in-, on-, or at-line control methods using spectroscopic or
  - 35 imaging techniques or chemometrics and data analysis, in a research and development
  - 36 environment.
  - 37 o Assessment of applications for marketing authorisation.
  - 38 o Use of spectroscopic techniques for the market surveillance of the quality of pharmaceutical
  - 39 substances or products.

40 **SIT Working Party (Second identification test)**

41 *Terms of reference*

- 42 • To support and advise the Commission, Groups of Experts or Working Parties on revision/suppression
- 43 of existing identification series, notably arising from the REACH regulation, where relevant.
- 44 Propose to the Commission further items for the work programme (such as replacements of methods not
- 45 in line with the available instrumentation in pharmacies or monographs with missing second
- 46 identification)

47 *Profile for experts*

- 1 • Pharmacists regularly involved in preparation of extemporaneous or stock preparation of medicinal
- 2 products in community pharmacies or hospitals as well as in the analysis of the pharmaceutical
- 3 substances used
- 4 • Pharmacists or chemists with special interest/expertise in analytical methods commonly available in
- 5 pharmacies
- 6 • Members of a regulatory authority

### 7 **ST Working Party (Standard Terms)**

#### 8 *Terms of reference*

- 9 • Development of standard terms and definitions for the Standard Terms database for dosage forms, units
- 10 of presentation, routes of administration, packaging and related terms at the request of Competent
- 11 authorities of Member States and certain non-member states (e.g. competent authority members of
- 12 ICH), the European Commission or the EMA.

#### 13 *Profile for experts*

- 14 • Current expertise in pharmaceutical dosage forms
- 15 • Several years of experience in one or more of the following fields:
  - 16 ○ Assessment of the pharmaceutical development part of applications for authorisation of
  - 17 medicinal products
  - 18 ○ Development of general monographs for dosage forms (group of experts or national
  - 19 pharmacopoeia secretariat)
  - 20 ○ Experience in formulation of medicinal products
- 21 • Members of the working party may be from a regulatory authority, universities

### 22 **SUT Working Party (Sutures)**

#### 23 *Terms of reference*

- 24 • Drafting and revision of texts in the field of sutures

#### 25 *Profile for experts*

- 26 • Expertise in pharmaceutical analytical methods, related to quality control of sutures and in development
- 27 of control methods
- 28 • Several years of experience in one or more of the following fields:
  - 29 ○ Quality control of sutures
  - 30 ○ Development of methods for control of sutures

### 31 **TCM Working Party (Traditional Chinese Medicines)**

#### 32 *Terms of reference*

- 33 • Drafting and revision of texts in the field of herbal drugs and herbal drug preparations preferably based
- 34 on the principle of adapting/improving existing monographs or methods to control herbal drugs used in
- 35 Traditional Chinese Medicines (TCM)
- 36 • Drafting general chapters related to the specific needs of TCM herbal drugs

#### 37 *Profile for experts*

- 38 • Current expertise in pharmaceutical analytical methods, related to quality control of herbal drugs and
- 39 herbal drug preparations and in development of control methods
- 40 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 41 monographs
- 42 • Several years of experience in one or more of the following fields:
  - 43 ○ Quality control of herbal drugs/herbal drug preparations in a manufacturing setting
  - 44 ○ Pharmaceutical quality control of herbal drugs and herbal drug preparations in an independent
  - 45 testing laboratory
  - 46 ○ Development of methods for control of herbal drugs

- 1           ○ Involvement in market surveillance or regulatory oversight of imported TCM herbal drugs
- 2       • **Essential:** Active involvement in laboratory verification of test methods for TCM herbal drugs and in
- 3       drafting of texts.
- 4       • Development of chromatographic separation systems for herbal drug constituents
- 5       • Knowledge in cultivation, harvesting, processing and use of TCM herbal drugs

#### 6 **VIT Working Party (Vitamins)**

##### 7 *Terms of reference*

- 8       • Drafting and revision of monographs in the field of vitamins and vitamin derivatives

##### 9 *Profile for experts*

- 10       • Current expertise in pharmaceutical analytical methods, related to quality control of vitamins and
- 11       excipients and in development of control methods. *The need of a specialist for vitamin D type*
- 12       *substances is highlighted*
- 13       • Access to laboratory facilities for verification and validation of methods proposed for inclusion in
- 14       monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of
- 15       texts.
- 16       • Several years of experience in one or more of the following fields:
- 17           ○ Quality control of vitamins in a pharmaceutical or bulk manufacturing setting
- 18           ○ Market surveillance of quality in an official control laboratory for medicines
- 19           ○ Pharmaceutical quality control in an independent testing laboratory
- 20           ○ Development of methods for control of vitamins in a research and development environment
- 21           ○ Method development and verification in a national pharmacopoeia laboratory
- 22           ○

#### 23 **WAT Working Party (Water)**

##### 24 *Terms of reference*

- 25       • Drafting and revision of texts in the field of water
- 26       • International harmonisation of relevant texts

##### 27 *Profile for experts*

- 28       • Current expertise in analytical methods applicable in water analysis in development of control methods
- 29       • Several years of experience in one or more of the following fields:
- 30           ○ Quality control of water in a pharmaceutical manufacturing setting
- 31           ○ Inspection of manufacturing sites
- 32           ○ Pharmaceutical quality control in an independent testing laboratory
- 33           ○ Development of methods for control of pharmaceutical waters in a research and development
- 34           environment
- 35

1 **TERMS OF REFERENCE AND PROFILE FOR MEMBERS OF**  
2 **“DORMANT” WORKING PARTIES:**

3  
4 *Once a working party has finalised its work programme i.e. the text(s) elaborated or revised by the working*  
5 *party has(have) been adopted by the Commission, the mandate of the working party can be extended as the*  
6 *support and advice of Pharmacopoeia members may still be needed e.g. by other Ph. Eur. groups or by the*  
7 *Secretariat to answer to questions users may rise when implementing the texts for example. The task of this*  
8 *working party will mainly consist in answering to enquiries, questions sent via the Secretariat i.e. by*  
9 *correspondence. The terms of reference of these working parties are described accordingly.*  
10

11 **CND Working Party (Conductivity)**

12 *Terms of reference*

- 13 • To provide support and advice in case of questions raised by e.g. users related to the PDG harmonised  
14 general chapter 2.2.38 *Conductivity*

15 *Profile for experts*

- 16 • Current expertise in conductivity measurement  
17 • Several years of experience in one or more of the following fields:  
18 ○ Quality control using conductivity measurement in a pharmaceutical manufacturing setting  
19 ○ Market surveillance of quality using conductivity measurement in a regulatory authority  
20 ○ Conductivity measurement for pharmaceutical analysis in an independent testing laboratory  
21 ○ Conductivity measurement in a regulatory authority  
22 ○ Development of methods for conductivity measurement in a research and development  
23 environment

24 **CRP Working party (Production and compounding of radiopharmaceutical preparations)**

25 *Objective*

- 26 • To provide support and advice in case of questions raised in the field of production and compounding of  
27 radiopharmaceutical preparations (especially chapter 5.19 *Extemporaneous preparation of*  
28 *radiopharmaceuticals*).

29 *Profile for experts*

- 30 • Knowledge of the current legal framework for the preparation or compounding of radiopharmaceuticals  
31 and quality control of such preparations, or experience in the licensing of such preparations  
32 • Several years of experience in the field of manufacture and quality control of radiopharmaceutical  
33 preparations and their starting materials in a pharmaceutical industry setting; in a PET centre or in a  
34 hospital

35 **GEL Working Party (Gelatin)**

36 *Terms of reference*

- 37 • To provide support and advice in case of questions raised by e.g. users in the field of gelatin

38 *Profile for experts:*

- 39 • Current expertise in pharmaceutical analytical methods, related to quality control of gelatin and in  
40 development of control methods  
41 • Access to laboratory facilities for verification and validation of methods proposed for inclusion in  
42 monographs, **Essential:** Active involvement in laboratory verification of test methods and drafting of  
43 texts.  
44 • Several years of experience in one or more of the following fields:  
45 ○ Quality control in a pharmaceutical or bulk manufacturing setting (gelatin or use of gelatin)  
46 ○ Market surveillance of quality in a regulatory authority

- 1           o   Pharmaceutical quality control in an independent testing laboratory
- 2           o   Method development and verification in a regulatory authority
- 3           o   Development of pharmaceutical control methods using near infrared spectrometry for gelatin
- 4           o   identification

#### 5   **HCP Working Party (Host-Cell Proteins)**

##### 6   *Objective*

- 7           •   To provide support and advice in case of questions raised by e.g. users related to the Chapter on Host
- 8           o   Cell Protein Assays (2.6.34) and propose potential revision of the chapter after evaluation of its
- 9           o   implementation

##### 10 *Profile for experts*

- 11          •   Current expertise in analytical methods and testing strategies related to quality control of residual levels
- 12          o   of host-cell proteins (including proteomic approaches)
- 13          •   Several years of experience in one or more of the following fields:
- 14           o   Quality control of recombinant proteins
- 15           o   Development and validation of manufacturing and purification processes for recombinant
- 16           o   proteins
- 17           o   Development and validation of in-house methods for host-cell protein detection and
- 18           o   quantification
- 19           o   Validation of commercial generic kits for a given protein and process
- 20           o   Assessment of the relevant parts of applications for marketing authorisations within a
- 21           o   medicines agency

#### 22 **HFA Working Party (Propellant Gases)**

##### 23 *Objective*

- 24          •   To provide support and advice in case of questions raised by e.g. users in the field of propellant gases

##### 25 *Profile for experts:*

- 26          •   Current expertise in pharmaceutical analytical methods, related to quality control of propellant gases
- 27          o   and in development of control methods
- 28          •   Several years of experience in one or more of the following fields:
- 29           o   Quality control of propellant gases in a pharmaceutical or bulk manufacturing setting
- 30           o   Assessment of the relevant parts of applications for marketing authorisation of medicinal
- 31           o   products containing propellant gases
- 32           o   Market surveillance of quality in a regulatory authority
- 33           o   Pharmaceutical quality control in an independent testing laboratory
- 34           o   Development of methods for control of propellant gases in a research and development
- 35           o   environment

#### 36 **LBP Working Party (Live Biotherapeutic Products)**

##### 37 *Terms of reference*

- 38          •   To provide support and advice in case of questions raised by e.g. users related to Live Biotherapeutic
- 39          o   Products

##### 40 *Profile for experts*

- 41          •   Current expertise in the development, production and/or quality control of Live Biotherapeutic Products
- 42          •   Several years of experience in one or more of the following fields:
- 43           o   development of Live Biotherapeutic Products
- 44           o   production of Live Biotherapeutic Products
- 45           o   assessment of applications for licensing of Live Biotherapeutic Products
- 46           o   micro-organism strain selection and batch production
- 47           o   microbiological techniques, molecular techniques applied to microbiology

1 **MQH Working Party (Microbiological Quality of Herbal Drugs)**

2 *Objective*

- 3 • To provide support and advice in case of questions raised by e.g. users and related to recommendations  
4 on microbiological quality of herbal drugs and herbal drug preparations
- 5 • Advising the Commission and its groups on acceptance criteria for microbiological criteria to be  
6 included in monographs

7 *Profile for experts:*

- 8 • Current expertise in pharmaceutical analytical methods, related to microbiological quality control of  
9 active substances and excipients and in development of control methods
- 10 • Several years of experience in one or more of the following fields:
- 11 ○ Microbiological quality control in a pharmaceutical or bulk manufacturing setting
- 12 ○ Market surveillance of quality in a regulatory authority
- 13 ○ Assessment of applications for marketing authorisation of herbal drugs and herbal drug  
14 preparations within an agency
- 15 ○ Development of microbiological methods for control of herbal drugs and herbal drug  
16 preparations in a research and development environment
- 17 ○ Pharmaceutical quality control in an independent testing laboratory
- 18 ○ Method development and verification in a regulatory authority

19 **MSL Working Party (Mesilates)**

20 *Objective*

- 21 • To provide support and advice in case of questions raised related to general methods drafted by the  
22 working party ie 2.5.37. Methyl, ethyl and isopropyl methanesulfonate in methanesulfonic acid, 2.5.38.  
23 Methyl, ethyl and isopropyl methanesulfonate in active substances, 2.5.39. Methanesulfonyl chloride in  
24 methanesulfonic acid, 2.5.40. Methyl, ethyl and isopropyl toluenesulfonate in active substances, 2.5.41  
25 Methyl, ethyl and isopropyl benzenesulfonate in active substances

26 *Profile for experts*

- 27 • Current expertise in pharmaceutical analytical methods, related to quality control of starting materials
- 28 • Access to laboratory facilities (including “hyphenated” techniques (LC-MS, GC-MS, etc.) for  
29 verification and validation of methods proposed for inclusion in monographs
- 30 • Several years of experience in one or more of the following fields:
- 31 ○ Quality control in a pharmaceutical manufacturing setting
- 32 ○ Quality control of starting materials for synthetic and semi-synthetic organic products in a bulk  
33 manufacturing setting
- 34 ○ Quality control using “hyphenated” techniques (LC-MS, GC-MS, etc.)
- 35 ○ Market surveillance of quality in a regulatory authority
- 36 ○ Quality control of starting materials in an independent testing laboratory
- 37 ○ Development of methods for control of starting materials in a research and development  
38 environment
- 39 ○ Method development and verification in a regulatory authority

40 **NMR Working Party (Nuclear Magnetic Resonance Spectrometry)**

41 *Objective*

- 42 • To provide support and advice in case of questions raised by e.g. users in the field of nuclear magnetic  
43 resonance spectrometry

44 *Profile for experts:*

- 45 • Current expertise in NMR, related to quality control of active substances and excipients and in  
46 development of control methods
- 47 • Several years of experience in one or more of the following fields:

- 1           ○ Quality control using NMR in a pharmaceutical or bulk manufacturing setting
- 2           ○ Market surveillance of quality in a regulatory authority
- 3           ○ Pharmaceutical quality control in an independent testing laboratory
- 4           ○ Development of pharmaceutical control methods using NMR in a research and development
- 5           environment

#### 6 **PHP Working Party (Pharmaceutical Preparations (general monograph))**

##### 7 *Objective*

- 8           • To support and advise Commission, Groups of Experts or Working Parties on revisions of the general
- 9           monograph Pharmaceutical Preparations, as needed. Such a need may arise e.g. from changed
- 10          requirements or from the need to replace repetitive references in monographs by a centrally listed
- 11          requirement in the general monograph Pharmaceutical Preparations.

##### 12 *Profile for experts*

- 13          • Extensive knowledge of pharmaceutical development and quality control of medicinal products
- 14          (licensed or unlicensed)
- 15          • Extensive knowledge of regulatory requirements and guidelines for medicinal products
- 16          • Several years of experience in one or more of the following fields:
  - 17           ○ Pharmaceutical development and quality control of medicinal products (licensed or
  - 18           unlicensed)
  - 19           ○ Assessment of the relevant parts of marketing authorisation applications in a medicines agency
  - 20           ○ Development of methods for testing of pharmaceutical preparations in a research and
  - 21           development environment, in a hospital or in a small-scale production setting
  - 22           ○ Market surveillance of pharmaceutical preparations in a regulatory authority
  - 23           ○ Inspection of retail or hospital pharmacies or of pharmaceutical companies

#### 24 **RCG Working Party (Raw Materials for the production of Cellular and gene transfer products)**

##### 25 *Objective*

- 26          • To provide support and advice in case of questions raised by e.g. users related to the general chapter on
- 27          *Raw materials of biological origin for the production of cell-based and gene therapy medicinal*
- 28          *products (5.2.12)* and propose potential revision of the chapter after evaluation of its implementation

##### 29 *Profile for experts*

- 30          • Current expertise in the development and/or quality control of cellular and gene transfer products and in
- 31          development of control methods
- 32          • Several years of experience in one or more of the following fields:
  - 33           ○ Development of cell and/or gene transfer products or raw materials used for their production
  - 34           ○ Development of cell culture methods/media
  - 35           ○ Assessment of applications for clinical trials and/or for marketing authorisations of cell and/or
  - 36           gene transfer products

#### 37 **SRP Working Party (Special Revision Programme)**

##### 38 *Terms of reference*

- 39          • To provide support and advice in case of questions raised by e.g. users related to the revision of the
- 40          related substances tests and limits in monographs in the field of active substances

##### 41 *Profile for experts*

- 42          • Current expertise in pharmaceutical analytical methods, related to quality control of active substances
- 43          and excipients and in development of control methods
- 44          • Access to relevant parts (chemistry of the active substance) of marketing authorisation dossiers in order
- 45          to judge the revision proposals
- 46          • Several years of experience in one or more of the following fields:

- 1           ○ Scientific coordination in a regulatory authority such as a National Pharmacopoeia Authority
- 2           ○ Assessment of the relevant parts (chemistry of the active substance) of applications for
- 3           marketing authorisation
- 4           ○ Market surveillance of quality in a regulatory authority
- 5           ○ Method development and verification in a regulatory authority
- 6       • Industry representatives are not appointed to the SRP Working Party; they contribute by submission of
- 7       data and interaction with the group via the Secretariat.

#### 8   **STA Working Party (Statistics)**

##### 9   *Terms of reference*

- 10       • To provide support and advice in case of questions raised by e.g. users in the field of statistical analysis

##### 11   *Profile for experts*

- 12       • Current expertise in statistical analysis, related to quality control of active substances, excipients and
- 13       medicinal products
- 14       • Several years of experience in one or more of the following fields:
  - 15           ○ Statistical analysis of results of control tests in a pharmaceutical manufacturing setting
  - 16           ○ Development of statistical methods applied in pharmaceutical analysis

#### 17   **WXT Working Party (Water for Extracts)**

##### 18   *Objective*

- 19       • To provide support and advice in case of questions raised by e.g. users in the field of water for the
- 20       preparation of extracts

##### 21   *Profile for experts:*

- 22       • Current expertise in analytical methods for water analysis, related to the water used for preparation of
- 23       extracts
- 24       • Several years of experience in one or more of the following fields:
  - 25           ○ Quality control of water used for the preparation of extracts in a pharmaceutical manufacturing
  - 26           setting
  - 27           ○ Assessment of the relevant parts of applications for marketing authorisation of extracts
  - 28           ○ Pharmaceutical quality control in an independent testing laboratory
  - 29           ○ Development of methods for control of water in a research and development environment

30